Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Returning from recess today, the House is set to consider the $128 billion “minibus” approved by the Senate on November 1, HR 2112. It covers FDA, NSF, the National Institute of Standards and Technology (NIST), and the Office of Science and Technology Policy (OSTP). More information can be found here. NIH is arguably the most important science agency not covered by the minibus. President Barack Obama proposed a $200 million, or 3% increase, to $31.7 billion. Senate Appropriations had approved, on September 21, $30.5 billion for NIH, while House Appropriations proposed (but has not voted on) $31.7 billion for the agency. Experts wonder if a bill that matches Obama in NIH spending could survive a Republican-controlled House. What are your predictions?